Nicotinamide mononucleotide is an anti aging molecule that helps increase the levels of nicotinamide adenine dinucleotide (NAD+) in the body. It is a precursor to NAD+ and can be found in a wide variety of foods.
NMN supplementation has been shown to reduce age-related oxidative stress, neurodegenerative complications, and cognitive impairment. The nutraceutical industry has aggressively marketed NMN. This substance has also been associated with Alzheimer’s disease.
Although NMN has been studied for its possible beneficial effects in the body, the safety of high doses has not been established. In order to determine whether NMN is safe, further clinical studies are needed.
A study on NMN in mice showed that it has the ability to reverse aging signs in the body. The treatment also exhibited anti-atherogenic effects.
NMN supplementation has also been shown to alleviate age-related sensory processing changes. Researchers also observed that NMN improved learning and memory performance. Moreover, the therapy reversal of age-related NAD+ decline was reported. NMN also reversed age-associated vascular mico-RNA expression.
Preliminary findings on the safety of NMN have shown that the compound is well-absorbed and does not cause detectable toxicity. However, further human studies should be conducted to determine the safety of the substance at high doses.
NiagenTM is a non-genotoxic form of NMN. It was tested on healthy mice, and its effects were non-debilitating.
The first phase I clinical trial was conducted on ten healthy volunteers. Researchers evaluated the time course of blood NMN concentration, bioavailability of NMN, and the safety of NMN in the human body.